Strata Critical Medical Lifts Full-Year Outlook as Q2 Revenue Jumps 61%
SRTA sits 48% above its 52-week low of $3.675.
Summary
Strata Critical Medical posted Q2 2026 revenue of $72.5M (+61% YoY) and raised full-year guidance, reflecting strong acquisition-driven growth in its clinical segment, even as cash reserves declined and non-cash charges led to a net loss.
Key Events · Earnings and Guidance · SRTA
-
Revenue Surges 61% to $72.5M
Revenue for Q2 2026 reached $72.5 million, a 60.7% increase year-over-year, propelled by the Clinical segment ($24.3M) from recent acquisitions and a 6.9% rise in Logistics.
-
Full-Year Guidance Raised
Management lifted 2026 revenue guidance to $285M-$295M and Adjusted EBITDA to $33M-$35M, up from the prior $29M-$33M, reflecting acquisition contributions and operational momentum.
-
Cash Reserves Halved to $16.3M
Cash and equivalents fell to $16.3 million from $31.0 million at year-end 2025, primarily due to $34.8 million in cash paid for three acquisitions during the quarter.
-
Non-Cash Charges Drive Net Loss
Despite strong operating performance, a $5.5 million non-cash fair value adjustment on contingent consideration and assets led to a net loss of $10.5 million, or $0.12 per share.
Analysis · SRTA · Industrial Applications And Services
A 61% surge in quarterly revenue to $72.5 million—fueled by recent acquisitions and organic gains in logistics and clinical services—underscores Strata Critical Medical's accelerating momentum. The company raised its full-year revenue and Adjusted EBITDA guidance, signaling confidence that the integration of three new acquisitions is on track and that demand for organ transplant logistics and perfusion services remains robust. Yet the quarter also revealed a halving of cash reserves to $16.3 million as capital was deployed for M&A, and a $5.5 million non-cash fair value charge pushed the bottom line to a $10.5 million net loss. The results confirm that the strategic pivot toward a clinical services roll-up is gaining traction, though the cash burn and integration risks warrant close attention.
At the time of this filing, SRTA was trading at $5.45 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $471.1M. The 52-week trading range was $3.68 to $6.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.